Earnings History Data for SAB Biotherapeutics, Inc. (SABS) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
SAB Biotherapeutics, Inc.
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29-03-2024 | ?? | SABS | SAB Biotherapeutics, Inc. | 38.93 | N/A | -0.64 | 0.00 | SAB Biotherapeutics GAAP EPS of -$7.64 misses by $3.43, revenue of $2.24M beats by $1.12M [3/29/2024 7:17 AM] |
4.28 | -0.26 (-5.72%) |
0.0 | 0.0 (0.00%) |
3.66 - 14.50 | 4,919 | 20,000 | 0 | ||
|
|
||||||||||||||||||
| 13-11-2023 | PM | SABS | SAB Biotherapeutics | 50.00 | -0.10 | -0.10 | 0.00 | SAB Biotherapeutics GAAP EPS of -$0.10 [11/14/2023 9:25 AM] |
0.92 | -0.01 (-1.08%) |
0.86 | -0.07 (-7.58%) |
0.37 - 1.45 | 13,450 | 60,000 | 4,350 | ||
| 21-08-2023 | PM | SABS | SAB Biotherapeutics | 41.00 | -0.14 | -0.16 | 0.00 | 0.7690 | 0.01 (1.05%) |
0.76 | 0.0 (0.03%) |
0.37 - 1.45 | 57,980 | 20,000 | 3,344 | |||
|
|
||||||||||||||||||
| 16-05-2023 | PM | SABS | SAB Biotherapeutics | 47.00 | -0.15 | -0.08 | 0.00 | SAB Biotherapeutics GAAP EPS of -$0.15 [5/16/2023 9:18 AM] |
0.7799 | -0.10 (-11.38%) |
0.81 | -0.07 (-7.77%) |
0.37 - 2.31 | 221,171 | 1,120,000 | 5,726 | ||
| 15-11-2022 | PM | SABS | SAB Biotherapeutics | 49.00 | -0.16 | -0.14 | 0.00 | SAB Biotherapeutics GAAP EPS of -$0.16 misses by $0.02 [11/15/2022 8:59 AM] |
1.08 | -0.17 (-13.61%) |
1.25 | 0.0 (0.00%) |
0.62 - 12.09 | 91,417 | 90,000 | 18,114 | ||
| 10-08-2022 | PM | SABS | SAB Biotherapeutics | 53.00 | -0.11 | -0.13 | 0.00 | SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03 [8/10/2022 8:22 AM] |
1.12 | -0.03 (-2.61%) |
1.14 | -0.01 (-0.87%) |
1.00 - 12.90 | 53,551 | 50,000 | 174 | ||
| 12-05-2022 | AH | After the close (May 12) |
SABS | SAB Biotherapeutics | 86.00 | -0.15 | -0.12 | 0.00 | SAB Biotherapeutics GAAP EPS of $0.02 [5/12/2022 5:11 PM] |
1.96 | 0.17 (9.66%) |
0.0 | 0.0 (0.00%) |
1.61 - 12.90 | 32,884 | 40,000 | 0 | |